Pure Global

A Food Effect Study of SPH5030 Tablets. - Trial NCT06372223

Access comprehensive clinical trial information for NCT06372223 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Pharmaceuticals Holding Co., Ltd and is currently Completed. The study focuses on Advanced Solid Tumor. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06372223
Phase 1
Completed
drug
Trial Details
ClinicalTrials.gov โ€ข NCT06372223
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Food Effect Study of SPH5030 Tablets.
A Single-center, Randomized, Open, Single-dose, Two-cycle, Two-sequence Crossover Food Effect Study of SPH5030 Tablets in Healthy Chinese Adult Subjects.

Study Focus

Advanced Solid Tumor

SPH5030

Interventional

drug

Sponsor & Location

Shanghai Pharmaceuticals Holding Co., Ltd

Chengdu, China

Timeline & Enrollment

Phase 1

Mar 04, 2024

Mar 25, 2024

16 participants

Primary Outcome

Peak Plasma Concentration (Cmax),Peak time๏ผˆTmax๏ผ‰,Area under the plasma concentration versus time curve (AUC)

Summary

The purpose of this study is to evaluate the food effect of SPH5030 tablets in healthy
 Chinese adult subjects.

ICD-10 Classifications

Carcinoma in situ, unspecified
Malignant neoplasm: Prepuce
Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm: Parametrium
Malignant neoplasm of other connective and soft tissue

Data Source

ClinicalTrials.gov

NCT06372223

Non-Device Trial